Educational Symposium
AKI and Hepatorenal Syndrome: Diagnosis, Management, and Treatment
November 08, 2025 | 12:45 PM - 01:45 PM
Location: Room TBD2, Hilton Americas-Houston
Session Description
AKI is common among individuals with cirrhosis and is linked to poor prognosis. Hepatorenal syndrome (HRS) type 1, now known as HRS-AKI, is a specific form of acute kidney dysfunction seen in patients with cirrhosis. Several interventions for kidney dysfunction in cirrhosis have been explored, including volume expansion with albumin and vasoconstrictors, such as midodrine, octreotide, norepinephrine, and, more recently, terlipressin. Distinguishing HRS-AKI from other causes of kidney dysfunction and selecting the right therapeutic approach remain challenging for clinicians managing patients with cirrhosis. This symposium illustrates the pathophysiology of different kidney dysfunction patterns in cirrhosis and proposes evidence-based treatment strategies.
Support is provided by an educational grant from Mallinckrodt Pharmaceuticals.
Learning Objective(s)
- Describe the pathophysiology of HRS-AKI
- Discuss etiologies, mechanisms, and workup of HRS-AKI
- Explain management and treatment strategies for HRS-AKI
Learning Pathway(s)
- AKI and Critical Care
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Pathophysiology of HRS-AKI
12:55 PM - 01:15 PM - Diagnosis and Management of Acute Kidney Dysfunction in Cirrhosis
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM